peters-Golden 1,2* interleukin (iL)−13 is a type 2 cytokine with important roles in allergic diseases, asthma, and tissue fibrosis. Its receptor (R) α1 is primarily responsible for the biological actions of this cytokine, while Rα2 possesses a decoy function which can block IL-13 signaling. Although the expression of Rα2 is known to be subject to modulation, information about its transcriptional regulation is limited. In this study, we sought to expand the understanding of transcriptional control of Rα2 in lung fibroblasts. We confirmed previous reports that IL-13 elicited modest induction of Rα2 in normal adult human lung fibroblasts, but found that prostaglandin E 2 (pGe 2) and fibroblast growth factor 2 (FGF-2)-mediators known to influence fibroblast activation in tissue fibrosis but not previously investigated in this regard-led to a much greater magnitude of Rα2 induction. Although both PGE 2 (via protein kinase A) and FGF-2 (via protein kinase B, also known as AKT) depended on activation of cAMP-responsive element-binding protein (cReB) for induction of Rα2 expression, they nevertheless demonstrated synergy in doing so, likely attributable to their differential utilization of distinct transcriptional start sites on the Rα2 promoter. Our data identify CREB activation via PGE 2 and FGF-2 as a previously unrecognized molecular controller of Rα2 gene induction and provide potential new insights into strategies for therapeutic manipulation of this endogenous brake on IL-13 signaling. Interleukin (IL)−13 is an important type 2 cytokine best known for its roles in allergic diseases and asthma 1 , but which also contributes to other inflammatory diseases such as Crohn's disease and ulcerative colitis 2 , tissue fibrosis 3,4 , and various forms of cancer 5-7. IL-13 recognition is complex, involving heterodimers comprised of three distinct receptor subunits. IL-13 receptor α1 (IL-13Rα1 or Rα1) has low affinity for IL-13, but when associated with the IL-4 receptor (IL-4Rα) subunit, ligand binding results in productive signaling via JAK/STAT6 8,9. IL-13 receptor α2 (IL-13Rα2 or Rα2) has greater affinity for IL-13, but its impact on signaling upon ligand binding depends on cell type and context 10,11. Rα2 lacks a cytoplasmic domain, and accordingly, many studies have reported that Rα2 fails to initiate signal transduction 10 and in fact, can act as a decoy receptor capable of binding ligand and thus preventing productive signaling through Rα1 12-15. On the other hand, more recent reports have identified cytoplasmic interactors for Rα2 16 and described Rα2-mediated activation of various intracellular signaling pathways 17-19. In keeping with such divergent signaling responses, Rα2 has been reported to both mediate and attenuate mouse models of allergic asthma 20-22 as well as pulmonary fibrosis 18,23,24. Although Rα1 is exclusively a membrane-bound receptor, mouse Rα2 has been shown to exist in membrane-bound as well as soluble forms, which reflect distinct splice variants 25,26. Although the soluble form does not exist ...